Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Díaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG; SCORED Investigators. Bhatt DL, et al. N Engl J Med. 2021 Jan 14;384(2):129-139. doi: 10.1056/NEJMoa2030186. Epub 2020 Nov 16. N Engl J Med. 2021. PMID: 33200891 Clinical Trial.
Epidemiology of diabetic kidney disease.
Reutens AT. Reutens AT. Med Clin North Am. 2013 Jan;97(1):1-18. doi: 10.1016/j.mcna.2012.10.001. Med Clin North Am. 2013. PMID: 23290726 Review.
A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.
Reutens AT, Jandeleit-Dahm K, Thomas M, Salim A, De Livera AM, Bach LA, Colman PG, Davis TME, Ekinci EI, Fulcher G, Hamblin PS, Kotowicz MA, MacIsaac RJ, Morbey C, Simmons D, Soldatos G, Wittert G, Wu T, Cooper ME, Shaw JE. Reutens AT, et al. Contemp Clin Trials. 2020 Mar;90:105892. doi: 10.1016/j.cct.2019.105892. Epub 2019 Nov 16. Contemp Clin Trials. 2020. PMID: 31740428 Clinical Trial.
The GIANT study, a cluster-randomised controlled trial of efficacy of education of doctors about type 2 diabetes mellitus management guidelines in primary care practice.
Reutens AT, Hutchinson R, Van Binh T, Cockram C, Deerochanawong C, Ho LT, Ji L, Khalid BA, Kong AP, Lim-Abrahan MA, Tan CE, Tjokroprawiro A, Yoon KH, Zimmet PZ, Shaw JE. Reutens AT, et al. Diabetes Res Clin Pract. 2012 Oct;98(1):38-45. doi: 10.1016/j.diabres.2012.06.002. Epub 2012 Jul 10. Diabetes Res Clin Pract. 2012. PMID: 22784926 Clinical Trial.
Residual proteinuria and eGFR predict progression of renal impairment within 2 years in type 2 diabetic patients with nephropathy who are receiving optimal treatment with angiotensin receptor blockers.
Ivory SE, Packham DK, Reutens AT, Wolfe R, Rohde RD, Lewis J, Atkins RC; Collaborative Study Group. Ivory SE, et al. Among authors: reutens at. Nephrology (Carlton). 2013 Jul;18(7):516-24. doi: 10.1111/nep.12053. Nephrology (Carlton). 2013. PMID: 23506627 Clinical Trial.
38 results